Active ingredients: ceftriaxone
What it is used for
Treatment of the following infections when caused by susceptible aerobic organisms. LOWER RESPIRATORY TRACT INFECTIONS. caused by Strep. pneumoniae, Streptococcus sp. (excluding Enterococci), methicillin sensitive Staph. aureus, H. influenzae, H. Parainfluenzae, Klebsiella sp. (including K. pneumoniae), E. coli, E. aerogenes, P. mirabilis and Serratia marcescens. SKIN AND SKIN STRUCTURE INFECTIONS. caused by methicillin sensitive Staph. aureus, methicillin sensitive Staph. epidermidis, Streptococcus group B, Streptococcus group G, Strep. pyogenes, Strep. viridans, Streptococcus sp. (excluding Enterococci), Peptostreptococcus sp., E. coli, E. cloacae, Klebsiella sp . (including K. pneumoniae and K. oxytoca), P. mirabilis, M morganii and S. marcescens. URINARY TRACT INFECTIONS (complicated and uncomplicated). Caused by E. coli, P. mirabilis, P. vulgaris, M morganii and Klebsiella sp. (including K. pneumoniae). UNCOMPLICATED GONORRHOEA (cervical/ urethral and rectal). Caused by N. gonorrhoeae, including both pencillinase and nonpenicillinase producing strains. BACTERIAL SEPTICAEMIA. Caused by Strep. pneumoniae, E. coli and H. influenzae. BONE INFECTIONS. Caused by methicillin sensitive Staph. aureus, methicillin sensitive Staph. epidermidis, Streptococcus group B, Strep. pneumoniae, Streptococcus sp. (excluding Enterococci), E. coli, Enterobacter sp., P. mirabilis and K. pneumoniae. JOINT INFECTIONS. Caused by methicillin sensitive Staph. aureus, Strep. pneumoniae, Streptococcus sp. (excluding Enterococci), E. coli, P. mirabilis, K. pneumoniae and Enterobacter sp. MENINGITIS. The initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by H. influenzae type b, N. meningitidis, Strep. pneumoniae or Enterobacteriaceae pending culture and sensitivity results. SURGICAL PROPHYLAXIS. The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. Susceptibility testing. Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Intravenous
- Store below 25 degrees Celsius
- Shelf lifetime is 2 Years.
Always read the label. If symptoms persist see your healthcare professional.
Clear glass vial containing a white to yellowish crystalline powder.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient ceftriaxone
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems